Legend Capital

临床试验

计划入组 51 人 · 首次发布于 2009 年 8 月 18 日

尚未招募

PACTR201806003389716

Capital Mãe

计划入组 446 人

尚未招募

NCT07756801

CAPITAL OFFLOAD-SHOCK

计划入组 456 人 · 首次发布于 2026 年 8 月 11 日

药物

查看全部 87 →

CD30-Targeted LCAR-HL30 Cells therapy(Legend Biotechnology)

LCAR-AIO(Legend Biotech)

CAR-T cell therapy

LB-2102(Legend Biotechnology)

生产企业：Legend Biotech

相关疾病：small cell lung cancer, large-cell neuroendocrine carcinoma

机构

查看全部 119 →

Legend Biotech

United States

Legend Biotech Corporation

United States

LEGEND LABZ, INC.

United States

资讯

查看全部 2952 →

9个月前

Allink Biotherapeutics Raises $47M to Advance Two ADC Programs in Global Phase I Trials

上个月

Beyang Therapeutics Closes Oversubscribed $30 Million Series A to Advance AI-Driven Drug Pipeline

去年

临床试验

Sprinter Legend Balloon Catheter

Capital Mãe

CAPITAL OFFLOAD-SHOCK

药物

CD30-Targeted LCAR-HL30 Cells therapy(Legend Biotechnology)

LCAR-AIO(Legend Biotech)

LB-2102(Legend Biotechnology)

机构

Legend Biotech

Legend Biotech Corporation

LEGEND LABZ, INC.

资讯

Allink Biotherapeutics Raises $47M to Advance Two ADC Programs in Global Phase I Trials

Beyang Therapeutics Closes Oversubscribed $30 Million Series A to Advance AI-Driven Drug Pipeline

Allink Biotherapeutics Secures $42 Million in Series A Funding to Advance Bispecific Antibody and ADC Pipeline